Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules

Karim, Aziz; Schubert, Elliot N.; Burns, Thomas S.; Palmer, Michael; Zinny, M. A.
June 1983
Angiology;Jun1983, Vol. 34 Issue 6, p375
Academic Journal
The article discusses disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules. Disopyramide phosphate is a type 1 antiarrhythmic drug used for suppression and prevention of recurrence of specific cardiac arrhythmias. It is freely soluble in water while the free base has a solubility of about 1 mg/ml. In healthy subjects, disopyramide phosphate is rapidly absorbed with an absorption half-life of about 30 minutes following a lag period of about 16 minutes. The extent of oral absorption is about 80% and there is clinically insignificant first-pass metabolism.


Related Articles

  • The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165 

    Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...

  • Disopyramide: Six Years' Experience. Wilson, Richard R.; Wallace, Andrew G. // Angiology;Jun1983, Vol. 34 Issue 6, p367 

    Since its approval by the FDA six years ago, oral disopyramide has earned a recognized role in the treatment of ventricular arrhythmias. During this time, clinical experience has refined our knowledge of this agent, allowing revision of dosing guidelines and better selection of patients. This...

  • Rythmodan.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on the rythmodan which is a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide, as in disopyramide phosphate. It is available as capsules and in a form for injection.

  • Vernakalant. Dia, Ederlyn Q.; Rathbun, Robert A.; Song, Jessica C. // Formulary;Aug2007, Vol. 42 Issue 8, p475 

    Atrial fibrilation (AF) is a disorder that affects >2 million people in the United States. First-line antiarrhythmic agents (per American College of Cardiology/American Heart Association/ European Society of Cardiology guidelines) that are currently used to treat recent-onset AF work by...

  • Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Diness, Thomas G.; Yung-Hsin Yeh; Xiao Yan Qi; Chartier, Denis; Tsuji, Yukiomi; Hansen, Rie S.; Olesen, Soren-Peter; Grunnet, Morten; Nattel, Stanley // Cardiovascular Research;Jul2008, Vol. 79 Issue 1, p61 

    Aims: Impaired repolarization in cardiac myocytes can lead to long QT syndrome (LQTS), with delayed repolarization and increased susceptibility to Torsades de Pointes (TdP) arrhythmias. Current pharmacological treatment of LQTS is often inadequate. This study sought to evaluate the...

  • Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias. Paulk Jr., E. Alan // Angiology;Feb1987 Part 2, Vol. 38, p198 

    Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease...

  • THE ELECTROPHYSIOLOGY OF NORPACE (PART III). Caracta, Anthony // Angiology;Jan1975 Part 2, Vol. 26, p120 

    Presents the electrophysiology of Norpace, an antiarrhythmic agents. Effects of disopyramide on the electrophysiological system of the A-V conducting system; Determination of the history of paroxysmal ventricular tachycardia; Mechanism of antiarrhythmic action.

  • Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs. Varró, András; Biliczki, Péter; Iost, Norbert; Virág, László; Kovács, Péter; Mátyus, Péter; Hála, Ottó; Papp, Julius Gy. // Current Medicinal Chemistry;Jan2004, Vol. 11 Issue 1, p1 

    One possible mechanism of action of the available K-channel blocking agents used to treat arrhythmias is to selectively inhibit the HERG + MIRP channels, which carry the rapid delayed rectifier outward potassium current (IKr). These antiarrhythmics, like sotalol, dofetilide and ibutilide, have...

  • Efficacy of Agents for Pharmacologic Conversion of Atrial Fibrillation and Subsequent Maintenance of Sinus Rhythm. Miller, Marlene R.; McNamara, Robert L.; Segal, Jodi B.; Kim, Nina; Robinson, Karen A.; Goodman, Steven N.; Powe, Neil R.; Bass, Eric B. // Journal of Family Practice;Nov2000, Vol. 49 Issue 11, p1033 

    CONTEXT Physicians have little evidentiary guidance for pharmacologic agent selection for atrial fibrillation (AF). OBJECTIVE To assess antiarrhythmic agent efficacy for AF conversion and subsequent maintenance of sinus rhythm (MSR). DATA SOURCE We searched the clinical trial database of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics